CN105920063B - 一种红毛五加叶提取物及其制备方法和用途 - Google Patents
一种红毛五加叶提取物及其制备方法和用途 Download PDFInfo
- Publication number
- CN105920063B CN105920063B CN201610258072.5A CN201610258072A CN105920063B CN 105920063 B CN105920063 B CN 105920063B CN 201610258072 A CN201610258072 A CN 201610258072A CN 105920063 B CN105920063 B CN 105920063B
- Authority
- CN
- China
- Prior art keywords
- extract
- acanthopanax giraldii
- giraldii harms
- acanthopanax
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 76
- 241000092717 Eleutherococcus giraldii Species 0.000 title claims abstract description 66
- 238000000605 extraction Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000002904 solvent Substances 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000005456 alcohol based solvent Substances 0.000 claims abstract description 3
- 230000036737 immune function Effects 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 99
- 239000003814 drug Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 abstract description 8
- 230000003647 oxidation Effects 0.000 abstract description 5
- 238000007254 oxidation reaction Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 230000001766 physiological effect Effects 0.000 abstract description 3
- 230000001066 destructive effect Effects 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 description 34
- 150000003254 radicals Chemical class 0.000 description 22
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 21
- 239000000523 sample Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 239000012488 sample solution Substances 0.000 description 14
- 230000002000 scavenging effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 230000003078 antioxidant effect Effects 0.000 description 10
- -1 tinctures Substances 0.000 description 10
- 244000269722 Thea sinensis Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 239000006286 aqueous extract Substances 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 description 5
- 108010006464 Hemolysin Proteins Proteins 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 239000003228 hemolysin Substances 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000382951 Hansenia forbesii Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005485 electric heating Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000092728 Eleutherococcus gracilistylus Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000597321 Hemiphanes Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- BYTCDABWEGFPLT-UHFFFAOYSA-L potassium;sodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[K+] BYTCDABWEGFPLT-UHFFFAOYSA-L 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种红毛五加叶提取物，它是以红毛五加嫩叶为原料，以水、醇类溶剂中的一种或两种以上的组合溶剂提取得到。本发明还提供了该提取物的制备方法和用途。本发明研究发现，红毛五加嫩叶提取物具有一定的改善免疫功能及抗氧化的作用，该类生理活性的发现更有利于对红毛五加叶的开发，同时有助于避免对其植株茎、枝条和根的毁灭性的割断或者采挖。
Description
技术领域
本发明涉及一种红毛五加叶提取物及其制备方法和用途。
背景技术
红毛五加为五加科五加属植物红毛五加Acanthopanax giraldii Harms的干燥茎皮，在四川、甘肃、宁夏、青海、湖北、陕西、河南等地均有分布，是藏族、壮族、瑶族、羌族、彝族、苗族、土家族等多民族常用药材；性温，味辛，无毒，入肝、肾经。五加科五加属植物的药用价值发现和利用历史悠久，五加属的植物大都具有滋补、抗炎、抗风湿、抗应激、抗病毒、抗肿瘤、降血糖、降血脂、提高免疫力等作用，临床上常用于治疗风湿痹痛、腰膝酸软等病症。红毛五加在四川阿坝藏族羌族自治州的小金县、金川县和茂县等地有较为丰富的野生资源分布，零星的人工种植；当地藏羌农牧民用其茎皮泡酒饮用，新鲜嫩叶炒食和煮汤、用开水烫后冰箱冷冻贮藏食用一年，认为其可以驱风除湿、强壮筋骨等功效。四川省宇妥藏药有限公司和西藏自治区昌都、林芝、亚东等地医药公司均以红毛五加为主要原料开发出保健食品。
红毛五为小灌木，主要野生分布在在四川藏羌高山、半高山的脆弱生态环境中，当地藏羌农牧民每年采集其茎皮或者枝皮30元/公斤左右销售给当地药材收购商，经济价值小；采取全部割断地上部分的主茎和枝条，然后趁植株茎新鲜时，用木棒敲击，分出茎皮和枝皮，废弃木心部分，该方法对该植物的可持续开发与利用、当地脆弱生态环境中的植被都是极大的破坏；目前，红毛五加野生植物资源已经越来越少，红毛五加的野生植物资源亟待在保护的前提下，进行科学、合理开发和综合利用。
国内外对于红毛五加的研究主要集中在其茎和根皮，而对具有植被保护和生态环境保护价值的红毛五加叶的研究较少。
发明内容
本发明的目的在于提供一种红毛五加叶提取物及其制备方法和用途。
具体地，本发明提供了一种红毛五加叶提取物，它是以红毛五加嫩叶为原料，以水、醇类溶剂中的一种或两种以上的组合溶剂提取得到。
本发明在研究过程中，还将红毛五加嫩叶经过杀青、炒制等工艺制备成茶，在相同的提取方法和条件下，茶的制备工艺较为繁琐，高温杀青过程会对样品中的绿原酸等活性成分造成破坏，因此本发明优选嫩叶为原料。嫩叶提取物在 0.2mg/ml以上浓度时，对DPPH、ABTS+自由基的清除能力与VC相近似。
进一步地，提取方法选自如下之一：(1)以水为溶剂进行提取；(2)以醇类溶剂或含水醇类溶剂进行提取；(3)先以醇类溶剂或含水醇类溶剂进行除杂，再用水提取。
更进一步地，所述提取方法为：以醇类溶剂或含水醇类溶剂进行提取。目前已经有报道称红毛五加叶水提物具有一定抗氧化活性，然而，本发明研究发现，采用上述方案制备的提取物，其抗氧化活性明显优于水提物(尤其是对DPPH自由基的清除能力)。
其中，所述醇类溶剂选自甲醇、乙醇或异丙醇。
本发明一个具体实施方式中，所述醇类溶剂选自乙醇。乙醇浓度选自80～95％v/v。本发明一个具体实施方式中，选用95％v/v乙醇。
本发明还提供了一种红毛五加叶提取物的提取方法，该方法选自如下之一：(1)以水为溶剂进行提取；(2)以醇类溶剂或含水醇类溶剂进行提取；(3)先以醇类溶剂或含水醇类溶剂进行除杂，再用水提取。
本发明还提供了上述红毛五加叶提取物在制备提高免疫的保健品或药品中的用途。
进一步地，所述保健品或药品是改善免疫抑制患者的体液免疫功能或/和巨噬细胞功能的保健品或药品。
本发明还提供了上述红毛五加叶提取物在制备具有抗氧化活性的保健品或药品中的用途。
进一步地，所述抗氧化是指清除自由基；更进一步地，所述自由基为DPPH。
进一步地，所述红毛五加叶提取物为红毛五加嫩叶的乙醇提取物。其中，乙醇浓度选自80～95％v/v。本发明一个具体实施方式中，选用95％v/v乙醇。该类提取物对DPPH自由基的清除能力显著优于其他提取物。
本发明还提供了一种提高免疫或抗氧化组合物，它是以上述提取物为活性成分制备而成。
组合物中可以根据具体需求添加相应的辅料或辅助性成分，将其制备成各种实用的剂型。
本发明可以采用本领域常规的制剂技术手段或制药方法，将本发明提取物制备成适当的保健品或药剂形式，包含：糖果、饮料、片剂，注射剂，酊剂，栓剂，胶囊剂，膏剂(软膏剂、乳膏剂)，丸剂，植入剂，糖浆剂，雾剂(气雾剂、粉雾剂、喷雾剂)，膜剂，颗粒剂，口服溶液剂(口服混悬剂、口服乳剂)，散剂，洗剂(冲洗剂、灌肠剂)，搽剂(涂剂、涂膜剂)，凝胶剂，贴剂等；优选为片剂，胶囊剂，眼用制剂。其中，所述片剂选自含片、舌下片、口腔贴片、咀嚼片、分散片、可溶片、泡腾片、缓释片、控释片、肠溶片等；所述注射剂选自针剂、 输液、冻干粉针、乳液、植入体、微球制剂、微丸制剂等；所述胶囊剂选自硬胶囊、软胶囊、缓释胶囊、控释胶囊和肠溶胶囊等；所述丸剂选自滴丸、糖丸等；所述颗粒剂选自混悬颗粒、泡腾颗粒、肠溶颗粒、缓释颗粒、控释颗粒等。
本发明所述辅料，是指除活性成分以外包含在保健品或药品中的物质，包括但不仅限于填充剂(稀释剂)、润滑剂(助流剂或抗粘着剂)、分散剂、湿润剂、粘合剂、矫味剂、增溶剂、抗氧剂、抑菌剂、乳化剂、崩解剂等。粘合剂包含糖浆、阿拉伯胶、明胶、山梨醇、黄芪胶、纤维素及其衍生物(如微晶纤维素、羧甲基纤维素钠、乙基纤维素或羟丙甲基纤维素等)、明胶浆、糖浆、淀粉浆或聚乙烯吡咯烷酮等；填充剂包含乳糖、糖粉、糊精、淀粉及其衍生物、纤维素及其衍生物、无机钙盐(如硫酸钙、磷酸钙、磷酸氢钙、沉降碳酸钙等)、山梨醇或甘氨酸等；润滑剂包含微粉硅胶、硬脂酸镁、滑石粉、氢氧化铝、硼酸、氢化植物油、聚乙二醇等；崩解剂包含淀粉及其衍生物(如羧甲基淀粉钠、淀粉乙醇酸钠、预胶化淀粉、改良淀粉、羟丙基淀粉、玉米淀粉等)、聚乙烯吡咯烷酮或微晶纤维素等；湿润剂包含十二烷基硫酸钠、水或醇等；抗氧剂包含亚硫酸钠、亚硫酸氢钠、焦亚硫酸钠、二丁基苯酸等；抑菌剂包含0.5％苯酚、0.3％甲酚、0.5％三氯叔丁醇等；调节剂包含盐酸、枸橼酸、氢氧化钾(钠)、枸橼酸钠及缓冲剂(包括磷酸二氧钠和磷酸氢二钠)等；乳化剂包含聚山梨酯-80、脂肪酸山梨坦、普流罗尼克F-68，卵磷酯、豆磷脂等；增溶剂包含吐温-80、胆汁、甘油等。
所述的辅助性成分，它具有一定生理活性，但该成分的加入不会改变上述提取物在疾病治疗过程中的主导地位，而仅仅发挥辅助功效，这些辅助功效仅仅是对该成分已知活性的利用，是本领域惯用的辅助治疗方式。若将上述辅助性成分与本发明提取物配合使用，仍然应属于本发明保护的范围。
本发明研究发现，红毛五加嫩叶提取物具有一定的改善免疫功能及抗氧化的作用，该类生理活性的发现更有利于对红毛五加叶的开发，同时有助于避免对其植株根茎的破坏。
附图说明
图1 DPPH清除率散点图
图2 ABTS+清除率散点图
图3还原力的比较
具体实施方式
提取前工艺：
烘干：将采摘的红毛五加嫩叶置于40℃电热鼓风干燥箱中干燥2天，并且要定期翻动，达到烘干均匀的效果。
制茶：挑选出鲜嫩的红毛五加叶片，去掉叶柄，摊开放置，定期轻翻动2～3 次，当顶叶下垂并失去光泽，手捏有弹性时进行杀青处理；杀青温度为200℃左右，时间为5min左右；将杀青后的五加嫩叶采用轻、重、轻的原则，揉捻5～6min，温度150℃左右，使叶片卷成条索，破碎叶细胞挤出汁，粘附于叶表面，手摸有润滑粘手的感觉即可；将成形的五加茶置于不锈钢筛网中装好，厚度为2cm左右，置入烘箱中烘干，温度设定为40℃，时间10h，取出即得。
实施例1 本发明各提取物的制备
水提物的制备：取一定量红毛五加嫩叶，加入10倍量水，浸泡30min，加热至水微沸，保持2h，过滤，滤液待用；取滤渣重复上述操作；合并两次滤液，即得嫩叶的水提物。将水提物进一步旋转蒸发浓缩至粘稠状，转移至表面皿中，冷冻干燥，即得嫩叶水提物干浸膏。
乙醇提取物的制备：取一定量红毛五加嫩叶，加入95％乙醇至样品表面完全浸没，冷浸提取72h，过滤，滤液待用；滤渣重复上述操作；合并两次滤液，即得嫩叶的乙醇提取物。将乙醇提取物进一步旋转蒸发浓缩至粘稠状，转移至表面皿中，真空干燥，即得嫩叶的乙醇提取物干浸膏。
醇提后水提物的制备：取醇提后的滤渣，挥干乙醇后按照水提物的制备方法制备，即得。
本发明中，“/”表示“或”。
下述实施例2、3中使用的提取物如下：
红毛五加茶水提物(简称：茶水提物，代号：B1，替换原料后按实施例1方法制备)，为棕褐色颗粒；红毛五加嫩叶水提物(简称：水提物，代号：B2)，褐色块状物；红毛五加嫩叶乙醇冷浸提取物(简称：乙醇冷浸提取物，代号：B3)，褐色浸膏；红毛五加嫩叶乙醇冷浸后水提物(简称：乙醇冷浸后水提物，代号：B4)，褐色浸膏。
实施例2 本发明提取物对免疫活性调整的研究
1、实验动物及环境条件
昆明种小鼠，SPF级合格动物，生产许可证号：SCXK(川)2013-19号。由四川省中医药科学院实验动物研究室提供。
本试验在国家中医药管理局二级实验室、四川省中医药管理局三级实验室中药药理实验室(TCM-2009-325)、四川省中药新药筛选与药理研究中心进行，应用设施符合SPF(三)级标准的动物实验室内进行。室内通过自动空调控制室温在19～21℃，相对湿度控制在40～70％。通过自动换气装置调节室内空气。人工控制荧光照明，每天8～20时明，20～8时暗。实验动物分笼饲养，动物每笼不超过5只，自由饮水，常规全价饲料，定时定量喂养。
2、试剂及仪器
注射用环磷酰胺，江苏恒瑞医药股份有限公司生产，批号：130032812，有效 期至：2015年2月，规格：0.2g×10瓶；氯化钠注射液(0.9％)，昆明南疆制药有限公司生产，规格：500mL:4.5g，批号：C130814A，有效期至：2015年7月。
Varioskan Flash全波长扫描式多功能读数仪，美国Thermo Scientific；UV-730生化分析仪：日本岛津生产；LXJ-64-01离心机：北京医疗仪器厂生产；JA1003电子天平，上海精科天平，d＝1mg；EB-3200D电子天平，由日本Shimadzu生产，d＝0.01g；YB电子天平，上海海康电子仪器厂生产，d＝0.1g；RB-200智能热板仪，成都泰盟软件有限公司；手术器械、秒表、直尺、灌胃针等。
3、试验方法
3.1红毛五加对小鼠网状内皮系统吞噬廓清能力的影响(碳廓清法)
取体重在18～22g小鼠80只，随机分成10组，按下表剂量分别给药或纯水，每天一次，给药7d后，除对照组外，各组动物肌注环磷酰胺注射液50mg.kg-1，共计2次，第12d给药后1h，每鼠按10mL.kg-1静脉注射用生理盐水稀释的25％印度墨水，注入墨水后1min和10min，分别从内眦静脉丛取血20μL，并立即将其加到2.0mL 0.1％Na2CO3溶液中。用分光光度计在675nm波长处测光密度值(OD)，以Na2CO3溶液作空白对照。将小鼠处死，取肝脏和脾脏，用滤级纸吸干脏器表面血污，分别称重。以吞噬指数表示小鼠碳廓清的能力。按下式计算吞噬指数K和校正吞噬指数a：
同上法重复实验一次，结果见表1、表2。
表1 红毛五加嫩叶提取物对网状内皮系统吞噬廓清能力的影响
注：*P<0.05，**P<0.01，与模型组比较，以下同
表2 红毛五加嫩叶提取物对网状内皮系统吞噬廓清能力的影响(重复试验)
红毛五加嫩叶茶水提物、水提物、乙醇冷浸提取物、乙醇冷浸后水提物8g生药·kg-1给药12d后免疫抑制小鼠吞噬指数均有较明显的提高，与模型组比较有统计意义(P<0.05或P<0.01)。提示红毛五加对免疫抑制小鼠网状内皮系统吞噬廓清能力(巨噬细胞功能)有促进作用。
3.2红毛五加对鸡红细胞所诱导小鼠血清溶血素抗体生成的影响
取体重在18～22g小鼠100只，随机分成10组，按下表剂量分别给药或纯水，每天一次，给药12d后，然后每鼠腹腔注射5﹪鸡红血球0.2mL免疫。免疫后各组动物继续给药，同时除对照组外，各组动物肌注环磷酰胺注射液40mg·kg-1，共计3次。小鼠免疫6d后，每鼠从眼眶取血约0.8mL，3000r/分离心，取血清10μL加入盛有1.0mL生理盐水的试管内，加入5﹪鸡红血球0.5mL，于水中再加1：10混合豚鼠血清0.5mL，摇匀后置37℃水浴中30min，取出后冰水浴终止反应，离心后取上清液1.0mL，加血红蛋白稀释液(都氏液)3.0mL混匀，静置10min，在波长处540nm比色，用OD值表示血清溶血素含量。结果见表3。
表3 红毛五加嫩叶提取物对鸡红细胞诱导小鼠血清溶血素生成的影响
红毛五加嫩叶茶水提物、水提物、乙醇冷浸提取物、乙醇冷浸后水提物8g生药·kg-1给药18d后对免疫抑制小鼠血清溶血素生成有较明显的提高，与模型组比较有统计学意义(P<0.01或P<0.05)。试验结果表明：红毛五加嫩叶水提物、乙醇冷浸提取物、乙醇冷浸后水提物4g生药·kg-1给药18d后免疫抑制小鼠血清溶血素生成有一定程度提高，提示红毛五加嫩叶对免疫抑制小鼠体液免疫反应有促进作用。
实施例3 本发明提取物抗氧化活性研究
机体在生命活动的氧化代谢过程中会不断产生各种活性氧自由基，独立存在，易损伤组织、引起各种疾病。在正常情况下，机体内的自由基处于动态平衡，但是一旦该平衡被打破，就会对机体造成损害，从而引发一系列相关疾病，因此需要我们提高防御机制，在日常生活中增加天然抗氧化剂的摄入量。本试验采用三种体外抗氧化指标比较红毛五加嫩叶提取物浸膏的对抗氧化活性能力。
1、仪器、试剂与药材
723型可见光光度计(上海光谱仪器有限公司)；Centrifuge 5804R(德国eppendorf)；FA1004N型电子天平(上海菁海仪器有限公司)；800型离心沉淀器(上海手术器械厂)；KH5200B型超声波清洗(昆山禾创超声仪器有限公司)；移液枪(德国eppendort)；DZKW-5-4型电热恒温水浴锅(北京市永光明医疗器械有限公司)；GZX—9420MBE型电热恒温鼓风干燥箱(上海博迅实业有限公司医疗设备厂)。
1，1-二苯基-2-苦肼基(DPPH)、ABTS+、维生素C、铁氰化钾、三氯化铁、三氯乙酸、磷酸氢二钠、磷酸二氢钠、丙酮、石油醚、氯仿、甲醇、乙醇、硫酸 亚铁、氢氧化钠、盐酸等均为国产分析纯。
2、方法
2.1清除DPPH自由基能力比较
DPPH无水乙醇溶液：称取0.004g DPPH，用80％无水乙醇定容至100mL容量瓶中，得到浓度为0.04mg/mL的DPPH溶液。置于4℃冰箱中，避光保存。
样品溶液：分别准确称取红毛五加不同浸膏样品0.200g，用80％无水乙醇溶解，转移至10mL容量瓶中，定容，作为样品溶液母液。从母液中准确移取0.01、0.05、0.10、0.20、0.40、0.60、0.80、1.00、1.20mL至10mL容量瓶中定容。
DPPH自由基清除能力的测定：分别取1.0mL不同浓度的红毛五加浸膏样品液于10mL具塞比色管中，依次向其中加入2.0mL DPPH乙醇溶液，为A1；向1.0mL不同浓度的红毛五加浸膏样品液中分别加入2.0mL的80％无水乙醇，为A2；向2.0mL DPPH乙醇溶液中加入1.0mL的80％无水乙醇，为A0。振荡混匀后，室温下避光放置30min后，在516nm处测定吸光度，以80％无水乙醇做空白对照，平行测定3次，计算清除率，以Vc做阳性对照，计算公式如下：
式中A0：DPPH溶液(2.0mL)+80％无水乙醇(1.0mL)
A1：DPPH溶液(2.0mL)+样品溶液(1.0mL)
A2：80％无水乙醇(2.0mL)+样品溶液(1.0mL)
备注：公式中引入A2是为了消除样品溶液本身颜色对实验测定的干扰。2.2清
除ABTS+自由基能力比较
ABTS+储备液的制备：准确称取37.84mg过硫酸钾，用去离子水溶解并定容至10mL的容量瓶中，即得浓度为140mmol/mL的A溶液。
准确称取38.40mg ABTS+标品，溶解并转移至10mL的容量瓶中，向其中加入1.0mL的A溶液，再用去离子水定容至刻度，在室温避光条件下静止16h，形成ABTS+储备液，临用时用去离子水稀释至吸光度为0.698～0.702(取1.0mL ABTS+储备液，稀释至50mL，吸光度值约为0.7)。
样品溶液：称取红毛五加不同的浸膏样品0.20g，用蒸馏水溶解，定容至10mL容量瓶中，做为样品溶液母液，从母液中准确移取0.01、0.05、0.10、0.20、0.40、0.60、0.80、1.00、1.20mL至10mL容量瓶中定容。
清除ABTS+自由基能力比较：分别取1.0mL不同浓度的浸膏样品溶液于10mL具塞比色管中，再向其中加入2.0mL的储备液，为A1；取1.0mL的不同浓度的浸膏样品溶液，再向其中加入2.0mL的去离子水，为A2；取一只试管向其中加入2.0mL的储备液和1.0mL的去离子水，为A0。震荡混匀后，室温避光下反应6min，在734nm波长下测定其吸光度。
式中A0：ABTS+储备液(2.0mL)+去离子水(1.0mL)
A1：ABTS+储备液(2.0mL)+样品溶液(1.0mL)
A2：80％无水乙醇(2.0mL)+样品溶液(1.0mL)
2.3 还原能力的比较
样品溶液：称取不同浸膏样品的红毛五加0.20g，用80％无水乙醇溶解，转移至10mL容量瓶中，定容，为母液。
0.20mol/L pH＝6.6磷酸盐缓冲液的配制：配制0.20mol/L的磷酸氢二钠100mL和0.20mol/L的磷酸二氢钠100mL，准确移取37.50mL的磷酸氢二钠和62.50mL磷酸二氢钠至100mL容量瓶中，即配成了pH＝6.6的磷酸盐缓冲液。
分别移取母液0.01、0.05、0.10、0.20、0.40、0.60、0.80、1.00、1.20mL至10mL容量瓶中，定容，为样品液。取样品液2.0mL，分别加入pH＝6.6的磷酸缓冲液2.5mL和1％铁氰化钾溶液2.5mL，混合后于50℃水浴锅中放置20min，取出后加入10％三氯乙酸2.5mL，而后于离心机中以3000转离心10min，取上层液2.5mL于10mL具塞比色管中，然后依次向其中加入去离子水2.5mL，0.1％三氯化铁0.5mL，混匀后静置10min，在700nm波长下测定吸光值。平行测定3次，以Vc做阳性对照。
本实施例中，浓度以浸膏量计算。
3 结果与分析
3.1 清除DPPH自由基能力比较
表4 DPPH清除率(IC50)
通过图1和表4表明：不同制备方法所得浸膏样品对于DPPH自由基均有较强的清除能力，且随着样品浓度的增加，其清除能力也逐渐增强，当样品浓度为0.4mg/mL时，样品对于DPPH的清除率达到最大值，进一步增大样品浓度，样品对于DPPH自由基的清除率均趋于平衡不再增大；Vc对于DPPH的最大清除率为94.5％；红毛五加嫩叶醇浸提物对于DPPH的清除率其次，最大清除率可达92.5％；五加茶水提物浸膏对于DPPH自由基的最大清除率值最低，但是也可以达到86.4％，其IC50值为0.079mg/mL。
3.2 清除ABTS+自由基能力比较
表5 ABTS+清除率IC50
如图2和表5所示：不同制备方法所得浸膏样品对于ABTS+自由基均有较强的清除能力，且随着样品浓度的增加，其清除能力也逐渐增强，当样品浓度为0.4mg/mL时，样品对于ABTS+的清除率达到最大值，进一步增大样品浓度，样品对于ABTS+自由基的清除率均趋于平衡不再增大；Vc对于DPPH的最大清除率为99.8％，其IC50值为0.003mg/mL；红毛五加嫩叶醇浸提物对于ABTS的最大清除率也可以达到99.8％；红毛五加嫩叶水提物浸膏对于DPPH自由基的最大清除率相对较低，为98.8％，其IC50值为0.0176mg/mL；红毛五加茶水提物对于ABTS+的最大清除率较嫩叶水提物高，但是其IC50最高，为0.0213mg/mL。
3.3 还原能力的比较
如图3所示，不同制备方法所得浸膏样品对于铁离子均有较强的还原能力，且随着样品浓度的增加，其还原能力逐渐增大。Vc的还原能力最强，当浓度为1.0mg/mL时，吸光度值为3.765；红毛五加嫩叶醇浸提后水提物样品的还原能力其次，在浓度为1.0mg/mL时，吸光度值为1.918；红毛五加茶水提物样品的还原能力最弱，在浓度为1.0mg/mL时，吸光度值为1.163。
4 小结
本试验采用多种体外抗氧化方法比较红毛五加不同浸膏样品进行体外抗氧化活性能力，试验结果表明：所有样品均有较好的清除DPPH、ABTS+自由基的能力，其中，嫩叶醇提物对DPPH自由基的清除能力最强，且与阳性对照VC相当；各提取物对ABTS+自由基的清除能力较为相似，且与阳性对照VC相当。
采用铁离子还原法比较红毛五加各样品的还原能力，其还原性以嫩叶醇提物略强。
3种评价指标结果均表明：
(1)红毛五加各样品随着其对应浓度增加抗氧化能力增强，呈较好的量效关系。
(2)嫩叶醇提物的抗氧化功效优于其他各提取物(尤其是对DPPH自由基的清除能力)，且令人意外的是，该提取物在0.2mg/ml以上浓度 时，对DPPH、ABTS+自由基的清除能力都与阳性对照VC相当，表现出了极强的自由基清除能力。
Claims (7)
1.红毛五加叶提取物在制备提高免疫的保健品或药品中的用途；所述红毛五加叶提取物是以红毛五加嫩叶为原料，以水、醇类溶剂中的一种或两种以上的组合溶剂提取得到。
2.根据权利要求1所述的用途，其特征在于：提取方法选自如下之一：（1）以水为溶剂进行提取；（2）以醇类溶剂或含水醇类溶剂进行提取；（3）先以醇类溶剂或含水醇类溶剂进行除杂，再用水提取。
3.根据权利要求2所述的用途，其特征在于：所述提取方法为：以醇类溶剂或含水醇类溶剂进行提取。
4.根据权利要求1～3任意一项所述的用途，其特征在于：所述醇类溶剂选自甲醇、乙醇或异丙醇。
5.根据权利要求4所述的用途，其特征在于：所述醇类溶剂选自乙醇。
6.根据权利要求5所述的用途，其特征在于：所述乙醇的浓度为80～95%v/v。
7.根据权利要求1所述的用途，其特征在于：所述保健品或药品是改善免疫抑制患者的体液免疫功能或/和巨噬细胞功能的保健品或药品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610258072.5A CN105920063B (zh) | 2016-04-25 | 2016-04-25 | 一种红毛五加叶提取物及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610258072.5A CN105920063B (zh) | 2016-04-25 | 2016-04-25 | 一种红毛五加叶提取物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105920063A CN105920063A (zh) | 2016-09-07 |
| CN105920063B true CN105920063B (zh) | 2020-06-16 |
Family
ID=56836865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610258072.5A Expired - Fee Related CN105920063B (zh) | 2016-04-25 | 2016-04-25 | 一种红毛五加叶提取物及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105920063B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420867A (zh) * | 2016-12-14 | 2017-02-22 | 成都中医药大学 | 一种红毛五加皮提取物及制备方法和用途 |
| CN107048384A (zh) * | 2017-03-27 | 2017-08-18 | 西南民族大学 | 红毛五加叶和百合耐缺氧用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101189995A (zh) * | 2006-11-22 | 2008-06-04 | 王宗耀 | 红毛五加茶 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005532992A (ja) * | 2002-01-25 | 2005-11-04 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー | 肝炎治療剤及び予防剤または肝臓保護剤として有用なソムオガルピ（ＡｃａｎｔｈｏｐａｎａｘＫｏｒｅａｎｕｍ）抽出物 |
| WO2010005146A1 (en) * | 2008-07-08 | 2010-01-14 | Ogapi Food Agricultural Union Corporation | Tablet containing acanthopanax sessiliflorus and vitamin and method manufacturing thereof |
| CN102579531A (zh) * | 2012-02-20 | 2012-07-18 | 山东大学威海分校 | 一种具有抗氧化作用的刺五加叶提取物 |
| CN103520235A (zh) * | 2013-10-25 | 2014-01-22 | 天津马克生物技术有限公司 | 一种具有降脂功能的植物组合物及其制备方法与应用 |
-
2016
- 2016-04-25 CN CN201610258072.5A patent/CN105920063B/zh not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101189995A (zh) * | 2006-11-22 | 2008-06-04 | 王宗耀 | 红毛五加茶 |
Non-Patent Citations (2)
| Title |
|---|
| 红毛五加叶水提液对羟自由基清除率的测定;杨鑫嵎;《安徽农业科学》;20111231;第39卷(第35期);第21653-21656页 * |
| 红毛五加茎皮中总皂苷超声提取工艺研究;吴莉莉;《西南民族大学学报·自然科学版》;20090731;第33卷(第3期);第536-537页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105920063A (zh) | 2016-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumar et al. | Recent trends in potential traditional Indian herbs Emblica officinalis and its medicinal importance | |
| CN102763786B (zh) | 用于改善肉鸡肉质及风味的饲料 | |
| CN1473594A (zh) | 玛咖根提取物 | |
| CN103315109A (zh) | 一种辣木茶天然植物饮料 | |
| Khursheed et al. | Phytochemical and pharmacological investigations on adhatoda zeylanica (medic.): A review | |
| CN104012731A (zh) | 一种百香果叶复合茶及其制作方法 | |
| CN105920063B (zh) | 一种红毛五加叶提取物及其制备方法和用途 | |
| Sachan et al. | In-Vitro & In-Vivo Efficacy Of Moringa Oleifera Plant Constituents In Urolithiasis As Antilithiatic Drug | |
| Ramgopal et al. | Evaluation of antilipidemic and anti-obesity efficacy of Bauhinia purpurea bark extract on rats fed with high fat diet | |
| CN103766901A (zh) | 一种穿心莲丙素在制备减肥食品或药品中的应用 | |
| CN101804083B (zh) | 松花粉及其提取物在治疗炎症性肠病中的用途及该提取物的制备方法 | |
| KR100609643B1 (ko) | 피부염 치료용 생약 조성물 및 그 제조방법 | |
| Areqi et al. | Effect of Capparis Cartilaginea Leaves Extracts on Indomethacin-Induced Gastric Ulcer in Experimental Animals | |
| CN113662975A (zh) | 一种藜麦提取物及其在制备预防胃黏膜损伤的药物和食品中的用途 | |
| KR101544000B1 (ko) | 생약 혼합물의 추출물을 함유하는 피부 미백용 조성물 | |
| KR20160086457A (ko) | 가미방기황기탕의 주정추출물을 포함하는 류마티스 관절염의 예방 및 치료용 조성물 | |
| CN112076292A (zh) | 一种具有增强免疫力和调节肾阴虚功能的粉剂及其制备方法 | |
| KR100927435B1 (ko) | 당뇨병 개선 및 완화용 환제 건강식품 및 이의 제조방법 | |
| CN108524850A (zh) | 一种用于增强免疫、防治心脑血管疾病的酒制剂 | |
| POPESCU et al. | The influence of extraction solvent on the active principles content of Portulaca Oleracea native species | |
| Sodamade et al. | nutritive evaluation, mineral composition and phytochemical analysis of leaf protein concentrates of Daucus carota | |
| KR20150033896A (ko) | 광물성 유황에 함유된 독성 제거 후 순수 유황 추출방법과 이를 활용하는 방법. | |
| KR100484312B1 (ko) | 땃두릅이 함유된 음료 | |
| CN108030800A (zh) | 一种提高男性精子质量的组合物 | |
| KR102651344B1 (ko) | 항염, 근육 증강, 관절 건강 및 연골 건강 개선용 식품 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200616 Termination date: 20210425 |